In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
The Sponsor had performed SD and MD PK, tolerability and safety trials in children 12-18 years of age in acute pain indication. The Sponsor intended to develop a pediatric program in chronic pain indication. Massive amount of PK, tolerability and safety data for the acute and chronic conditions were available in adults.
Could M&S replace the chronic pain SD clinical trial in children 12- 18 years of age and predict the optimal PK sampling scheme for the MD trial?
The compound had a “well behaved” pharmacokinetic profile. PBPK modeling was already successfully applied from adults to children in the acute program. PBPK modeling was applied in chronic pain as well.
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
In silico clinical trial to support label extension.
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved